The short version.
MOTS-c's original characterization wasn't about endurance — it was about metabolism. The Cohen lab found that MOTS-c regulates glucose handling and insulin sensitivity, and that its levels change with metabolic stress. In animals, exogenous MOTS-c improves insulin sensitivity, reduces obesity-induced metabolic dysfunction, and activates AMPK — the cellular energy-sensing pathway also engaged by metformin and exercise.
That's why people search for MOTS-c around metabolism: insulin resistance, metabolic flexibility, and the broader picture of mitochondrial dysfunction in modern lifestyle disease.
What the literature actually says.
Animal data on MOTS-c and metabolism is consistent: improved glucose disposal, reduced insulin resistance under high-fat-diet conditions, and AMPK pathway activation. The mechanistic story holds up well in preclinical models.
Human data is earlier. There are observational findings — circulating MOTS-c levels correlate with insulin sensitivity in some cohorts — but the trial base for exogenous MOTS-c in metabolic populations is thin. As with most mitochondrial peptides, the gap between mechanistic plausibility and clinical proof is real.
The honest framing: if you're metabolically healthy, MOTS-c probably isn't the lever to pull first. If you're someone with insulin resistance, prediabetes, or post-GLP-1 metabolic concerns, MOTS-c is mechanistically interesting — but it's an adjunct, not a primary therapy, and the evidence supporting it lags behind what we have for established options.
MOTS-c is mechanistically interesting in metabolism. It's an adjunct, not a primary therapy.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Should we characterize fasting insulin, HOMA-IR, A1c before adding MOTS-c?
- Are evidence-supported tools (metformin, lifestyle, GLP-1 if indicated) sequencing first?
- How long do we run MOTS-c before reassessing the metabolic markers?
- What signals would tell us this isn't doing what we hoped?
- Does MOTS-c stack sensibly with other interventions, or do we run it alone first?
Sources